Skip to main content
New Year’s Sale — Build a balanced news diet with 40% off Vantage
Published loading...Updated

Experimental drug targets early toxic amyloid to slow Alzheimer’s disease

NU-9 sharply lowered a toxic amyloid beta subtype and reduced brain inflammation in early-stage Alzheimer's mice, showing promise for early intervention before symptoms emerge.

Summary by Medical Xpress
An experimental drug developed at Northwestern University has demonstrated further promise as an early intervention for Alzheimer's disease.

8 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

northwestern.edu broke the news in on Thursday, December 18, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal